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Abstract
Background—0.6–12.7% of patients with primary cutaneous melanoma will develop additional
melanomas. Pathologic features of tumors in patients with multiple primary cutaneous melanomas
have not been well described. In this large international multi-center case-control study, we
compared the clinicopathologic features of a subsequent melanoma with the preceding (usually the
first) melanoma in patients with multiple primary cutaneous melanomas, and with those of
melanomas in patients with single primary cutaneous melanomas.
Methods—Multiple primary melanoma (cases) and single primary invasive melanoma (controls)
patients from the Genes, Environment and Melanoma (GEM) study were included if their tumors
were available for pathologic review and confirmed as melanoma. Clinicopathologic
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characteristics of invasive subsequent and first melanomas in cases and invasive single melanomas
in controls were compared.
Results—473 pairs comprising a subsequent and a first melanoma and 1989 single melanomas
were reviewed. Forward stepwise regression modeling in 395 pairs with complete data showed
that, compared to first melanomas, subsequent melanomas were: more commonly contiguous with
a dysplastic nevus; more prevalent on the head/neck and legs than other sites; and thinner.
Compared with single primary melanomas, subsequent melanomas were also more likely to be:
associated with a contiguous dysplastic nevus; more prevalent on the head/neck and legs; and
thinner. The same differences were observed when subsequent melanomas were compared with
single melanomas. First melanomas were more likely than single melanomas to have associated
solar elastosis and no observed mitoses.
Conclusions—Thinner subsequent than first melanomas suggest earlier diagnosis, perhaps due
to closer clinical scrutiny. The association of subsequent melanomas with dysplastic nevi is
consistent with the latter being risk factors or risk markers for melanoma.
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INTRODUCTION
In patients with primary cutaneous melanoma (hereafter referred to as melanoma), the
reported incidence of a second or higher order melanoma ranges between 0.6% and
12.7%.1–3 In patients with one melanoma, a family history of melanoma confers an
increased risk for a subsequent melanoma.2, 4–12 Many studies based on data from single
centers, and a few based on population data, have shown that patients with non-familial
melanoma also have an increased risk of developing additional melanomas.1–5, 7–10, 13–33
The relative risk of additional melanomas is highest in the first year after diagnosis of the
first melanoma and decreases progressively with time, but is increased for at least 20
years.1, 25
Most studies of multiple melanomas have detailed the clinical and genetic characteristics of
affected patients, but pathologic features of tumors in patients with MPMs have been
incompletely described. To date, the pathologic features assessed have been limited to
thickness and Clark level,8, 34 associated dysplastic nevus,2, 17 and, rarely, ulceration2, 21
and regression.16 A detailed comparison of the pathologic differences between tumors in
patients with multiple primary melanomas has not been reported.
In the Genes, Environment and Melanoma (GEM) Study, a large international multi-
institution case-control study, we sought to examine in detail the clinicopathologic features
of melanomas in patients with multiple primary melanomas (GEM cases) and to contrast
features of the subsequent melanoma with those of the preceding, usually the first,
melanoma, in these patients. Furthermore, we compared the clinicopathologic features of
both the subsequent and first melanoma in cases with features of the melanoma in patients
with single primary melanomas (GEM controls). The aim of the study was to determine
whether there were significant differences in clinicopathologic features between these
groups.
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Patients and selection criteria
The Genes, Environment and Melanoma (GEM) Study35 has investigated genetic and
environmental risk factors in cutaneous melanoma patients with newly incident multiple and
single primary tumors identified in eight population-based cancer registries in Australia,
Canada, Italy and the United States and one hospital center estimated to cover around 50%
of the melanomas diagnosed in the state of Michigan. The GEM study is designed as a case
control study in which the population at risk is survivors of a first primary melanoma.
Controls were diagnosed with a first invasive primary melanoma in 2000 and cases had a
newly incident second or higher order invasive or in situ melanoma in 2000–2003 and, in
four centers, in 1998 and 1999 also. We used incident sampling to identify both GEM cases
and GEM controls and also ascertained the preceding (usually the first) melanoma in GEM
cases in local cancer registry records (average 47 months between the first and the
subsequent, case-defining melanoma). Further details of the study design and its rationale
have been published.35
The Study was approved by the appropriate institutional review committees and met the
guidelines of the responsible governmental agencies. For the analyses in this report, GEM
Study participants with single primary melanomas (controls) or multiple primary melanomas
(cases) were included if their tumors were confirmed as invasive melanoma and were
available for pathologic review by an experienced dermatopathologist. Patients whose
tumors were entirely in situ (some subsequent melanomas in GEM cases) were excluded.
In cases, clinicopathologic characteristics of the newly incident subsequent melanoma and
their preceding, usually first, melanoma were compared; we refer to these melanomas as
‘subsequent’ and ‘first’ for convenience. The order of diagnosis of the multiple melanomas
could not be determined for some cases because diagnosis month and year only were
obtained for the study; thus multiple melanomas with the same month of diagnosis were
treated as simultaneously diagnosed and excluded from this comparison. There was a shorter
time between diagnosis of the subsequent and first melanoma in cases in this analysis (mean
47 months, interquartile range (IQR) 10–72) than in all GEM cases (mean 72 months, IQR
14–110); this is probably explained by the greater difficulty of gaining access to pathology
sections or slides suitable for review of first melanomas diagnosed longer ago. In separate
analyses, clinicopathologic features of the subsequent and first melanomas in cases were
compared with the single melanomas in controls. The clinicopathologic characteristics
assessed in each melanoma are listed in Tables 1 and 2.
Statistical methods
Our primary analyses compared the clinicopathologic characteristics of subsequent and first
melanomas in individual cases by estimating prevalence ratios (subsequent compared with
first melanoma) using Cox regression models with equal survival times given to each subject
and robust variance. This method gives unbiased effect estimates and confidence intervals
and is superior to the use of logistic regression, in which odds ratio estimates of prevalence
ratios are non-conservatively biased.36 Analyses were clustered on individual cases to
account for within case correlation and adjusted for age at diagnosis, sex and study center.
The variables ‘site of melanoma’ and ‘presence of mitoses’ were included in the
multivariable models instead of the variables ‘location on exposed sites’ and ‘mitotic rate’
due to their smaller p-values in the univariate analysis. A p-value of <0.2 in the single
variable analyses was used as a cut-off for entry into a forward stepwise multiple regression
model of all clinicopathologic characteristics. The analyses comparing each of subsequent
and first melanomas with single melanomas also estimated prevalence ratios in models
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adjusted for age, sex and study center but did not cluster on individual patients; a forward
stepwise regression approach was again used. Only patients with valid values for all
pathology variables were included in the stepwise analyses.
RESULTS
There were 3,676 patients in the GEM study population, of whom 2,470 had a single
primary melanoma and 1,210 had multiple primary melanomas. Following pathology
review, 1,214 (33.0%) patients were excluded because pathology slides were not available
for review, primary tumor was missing from the slides available or the review diagnosis was
missing (866, 23.6%); or slide review classified the index tumor as ‘not melanoma’ (67,
1.8%) or ‘in situ melanoma’ (281, 7.6%). Totals of 473 cases with invasive multiple
(subsequent and first) melanomas and 1989 controls with single melanomas were available
for the analysis; 78 of the former were excluded, however, because they had the same month
of diagnosis and were considered to have been diagnosed simultaneously. The age and sex
distribution of the included patients (Table 1) was similar to all GEM participants. In the
main GEM study, cases were generally older than GEM controls and the female/male ratio
fell with age, reflecting the higher rate of increase in melanoma incidence with age in men
than in women.35 More than half (58%) of the 473 patients with multiple melanomas in this
report had their most recent melanoma diagnosed within 3 years of the preceding melanoma,
compared with 52% of all 1,210 GEM multiple melanoma patients.
There were a number of sizeable differences in clinicopathologic characteristics between the
subsequent and first melanomas (Table 2). The subsequent melanomas were more often
located on the head and neck than MPM1 (23% vs. 16%), though the trunk was the
dominant site for both subsequent and first tumors; 50.2% of the subsequent tumors in males
and 24.6% in females were on the trunk (Table 1). The subsequent melanomas were more
often lentigo maligna melanoma histologic subtype (23% vs. 14%), though 57% of pairs
were of the same histologic type, they were thinner (77% vs. 68% ≤1.0mm thick), more
often Clark level II (60% vs. 48%) or were lacking vertical growth (57% vs. 46%). A higher
proportion of subsequent than first melanomas was associated with remnants of a contiguous
dysplastic nevus (24% vs. 15%) and more often had an associated in situ component (92%
vs. 89%), marked solar elastosis (24% vs. 20%), mitoses rated as absent (66% vs. 63%), and
occurred on a usually exposed site (29% vs. 26%),. Adjusting for age at diagnosis did not
produce materially different results from those in Table 2. Generally speaking, differences
between MPM2 and single primary melanoma were similar to but greater than those
between MPM2 and MPM1 (Table 2).
There were no material differences between subsequent melanomas diagnosed within 1–3
months of the first melanoma (synchronous melanomas) and those diagnosed 3 months or
more after it (metachronous melanomas). However, when we compared melanoma pairs
with <3 years and ≥3 years between tumours, the subsequent melanomas diagnosed in the
later interval were more likely than those diagnosed in the earlier interval to be of nodular
and unclassified type (20% vs 8%), >1mm thick (31% vs 16%), Clark level IV or V (46% vs
34%) and to have mitoses (39% vs 28%) (p<0.05 in each case; results not shown).
Apart from the higher prevalence of subsequent melanomas on the head and neck, the site
distributions of subsequent and first melanomas were similar. There was a weak degree of
concordance within pairs by body site (46%; Kappa 0.22, 95% CI: 0.21–0.35; p<0.001).
Only a co-existing nevus, location on the head and neck or legs and less deep invasion
(whether assessed by Breslow thickness, Clark level or presence of vertical growth) were
identified as independently more likely to be present in subsequent melanomas than in first
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melanomas in the forward stepwise regression model (which included adjustment for age at
diagnosis, sex and center, Table 3). The model fit was marginally poorer when either Clark
level or Breslow thickness was substituted for vertical growth (results not shown). There
were no differences between the directions of the associations of these variables with MPM2
in the multivariable model (Table 3) and those in the single variable analyses (Table 2).
Only two characteristics appeared important in a forward stepwise regression model
(adjusted for age, sex and center) comparing first melanomas in multiple melanoma patients
(cases) with single melanomas (controls): mitoses were present less often (prevalence ratio
(PR) 0.79, 95% CI 0.65–0.96) in first melanomas than in single melanomas and mild/
moderate (PR 1.43, 95% CI 1.11–1.84) and marked solar elastosis (PR 1.41, 95%CI 1.04–
1.93) was present more often (results not shown). In a similar analysis comparing
subsequent melanomas with single melanomas, having a contiguous dysplastic nevus (PR
1.45, 95%CI 1.15–1.83), less frequent vertical growth (PR 0.79, 95%CI 0.63–0.99) and
location on the head and neck (reference category, PR 1.00) or legs (PR 1.05, 95% CI 0.76–
1.46) were associated more often with subsequent melanomas than single melanomas(results
not shown). These results are similar to those for the comparison of subsequent and first
melanomas (Table 3).
DISCUSSION
We examined many histopathologic and some clinical characteristics of multiple melanomas
and found that subsequent melanomas in patients with multiple melanomas were more likely
than than their first melanomas to have evidence of a contiguous dysplastic nevus, to have
invaded less, and to be located on the head and neck or legs.
In studying patients with multiple melanomas, it is important to ensure that the subsequent
melanomas are independent primary tumors and not cutaneous metastases from an
antecedent primary melanoma. Classifying cutaneous melanomas as primary or secondary
solely on histologic grounds may be challenging.37 More reliable classification is based on
correlation of several clinical and pathologic features, such as location, the presence of an
associated precursor/in-situ lesion, lymphatic invasion and dense lymphocytic inflammation,
although both primary and metastatic melanomas may share some of these characteristics. In
a recent study, Orlow and colleagues38 compared the somatic mutational profiles of pairs of
melanomas designated as independent primary tumors on the basis of their clinical and
pathologic characteristics. They found no significant evidence of clonal origin of the two
primaries in 17 of the 19 patients examined by molecular profiling using a set of highly
polymorphic genetic markers. These results suggest that most second melanomas designated
clinically and pathologically as independent primary tumors are indeed independent
occurrences of the disease, supporting the validity of the criteria used by experienced
clinicians and pathologists in distinguishing new primaries from metastases.
Pathologic features of tumors in patients with multiple melanomas have been incompletely
reported to date. Most commonly, subsequent melanomas have been reported to have
invaded less than preceding melanomas, both in terms of Breslow thickness20–22 and Clark
level.8, 27 Studies that included in situ melanomas reported that a greater proportion of
subsequent melanomas were in situ.2, 3, 20, 21, 29, 39 Although melanomas that were
exclusively in situ were excluded from the present analysis, invasive subsequent melanomas
were more commonly associated with an in situ component (92%) than preceding
melanomas (89%) and single melanomas (88%). The high prevalence of an associated in
situ component supports the proposition that the subsequent melanomas in patients with
multiple melanomas in this study were primary at the site of diagnosis.
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We observed a weak but significant concordance between the sites of occurrence of multiple
melanoma pairs. While a significant correlation between their sites has not been reported in
most studies,8, 10, 14, 16, 20, 22, 40 several studies19, 34, 39 did find site concordance ranging
between 52% and 56%. Some degree of site concordance between melanomas in the same
patient would be expected because the same patterns of sun exposure and sun protection
underlie the occurrence of both lesions. The comparatively weak site concordance and the
fact that subsequent melanomas are diagnosed synchronously (within three months) with the
first melanoma in up to 60% of patients with multiple melanomas (27% of the 395 pairs in
the present study – results not shown)21 highlight the need for careful and complete skin
examination when assessing patients with melanoma.39, 41, 42 Moreover, the increased risk
of metachronous melanomas, the long intervals (>20 years1) within which they may be
diagnosed, and the probable benefits of early diagnosis of additional melanomas and
metastatic disease suggest that patients with one melanoma may benefit from regular follow
up.27, 43 This suggestion is strengthened by our findings that subsequent melanomas
diagnosed ≥ 3 years after a first, when perhaps clinical follow-up has become less intense or
ceased, were thicker, more likely to be of nodular type and to have mitoses, than subsequent
melanomas diagnosed within 3 years of the first.
In addition to the greater site concordance of multiple melanomas, subsequent melanomas
were more likely than first melanomas to be on the head and neck or legs than on the upper
limbs or trunk. This too might be expected, at least for the head and neck, because of the
head and neck’s generally greater exposure to the sun and greater risk of melanoma per unit
of surface area than other body sites, particularly in older people.44, 45 This possible
association of multiple melanomas with higher sun exposure is supported by the stronger
association of solar elastosis with first melanomas than single melanomas in the present
study, observed associations of high sun exposure44 and lack of sunscreen use4 with an
increased risk of multiple melanomas, and the finding that solar exposure at any age was
associated with increased risk of developing multiple primary melanomas in the GEM
study.46
Superficial spreading melanoma, lentigo maligna melanoma and nodular melanoma were, in
decreasing order, the commonest histologic subtypes in each of subsequent, first and single
primary melanomas in our study. Scheibner et al16 found the commonest subtypes to be
superficial spreading melanoma and nodular melanoma, and that each of subsequent and
first melanomas were of the same histologic type in 74% of cases, which compares with
54% in the present study. The prominence of lentigo maligna melanoma in our study
probably reflects refined diagnostic criteria and better clinical recognition of this subtype of
melanoma, as well as the common occurrence in Australian populations (42% of melanomas
in this analysis were from the Australian GEM center – data not shown) of high solar UV
exposure, which is well known to be associated with lentigo maligna melanoma.47
Ulceration has previously been shown to be less common2, 21 and regression to be more
common16 in subsequent than in first melanomas. Consistently, ulceration was less common
in subsequent melanomas in our study, which is in keeping with the lesser thickness of these
tumors and a known correlation of ulceration with tumor thickness,48 and regression was
more common, but both could have been chance differences. The difference between our
findings for regression and those of Scheibner et al16 may be due to the fact that there is
considerable interobserver variation in, and poor reproducibility of, the histologic
assessment of regression.49, 50
Similarly to our study, dysplastic nevi have been found to occur more frequently in patients
with multiple (38–63%) than single primary melanomas17, 22 and in the general
population.51 These observations suggest that dysplastic nevi are markers of risk for
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additional melanomas. They are in keeping with results of previous studies, which have
shown that the presence of clinically and histologically diagnosed dysplastic nevi,5, 33 a
family history of dysplastic nevi,4 and classical atypical mole syndrome20 are associated
with increased risk of multiple primary melanomas. Dysplastic nevi are also risk markers for
the development of melanoma in melanoma-prone families.52–54 However, it is generally
easier to detect a nevus remnant in thin melanomas (e.g. subsequent melanomas in patients
with multiple melanomas) than in thick melanomas (e.g. first melanomas), as in the latter
any residual nevus may have been overgrown by the invasive melanoma.
Differences in pathology between the paired melanomas in patients with multiple tumors,
notably the reduced thickness and vertical growth in subsequent melanomas, are likely to
reflect closer clinical surveillance and earlier diagnosis. Other differences, such as the more
common occurrence of dysplastic nevi in association with subsequent melanomas, and the
stronger association of subsequent melanomas with the most exposed body site (head and
neck) are consistent with dysplastic nevi and sun exposure being risk factors or risk markers
for and, in the case of dysplastic nevi, possible precursors to additional melanomas in
patients with a cutaneous melanoma.
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Table 3
Results of a stepwise multiple regression analysis to identify variables that independently distinguished
subsequent from first melanomas in patients with multiple primary melanomas
Pathology variables Tumor Prevalence ratios† (95% CI) for MPM2 p-value
First melanoma* Subsequent melanoma*
Co-existing nevus <0.001
 Not identified 226 227 1.0
 Dysplastic 54 83 1.29 (1.10–1.53)
 Common acquired 54 22 0.61 (0.43–0.87)
 Congenital & other 2 4 1.78 (0.97–3.29)
Vertical growth 0.01
 Absent 157 191 1.0
 Present 179 145 0.82 (0.70–0.95)
Site of melanoma 0.04
 Head & neck 56 78 1.0
 Trunk 156 143 0.81 (0.68–0.96)
 Arms 61 48 0.78 (0.60–1.02)
 Legs 63 67 0.98 (0.81–1.19)
*
First and subsequent melanomas are primary invasive cutaneous melanomas in patients with multiple primary melanomas.
†
Prevalence ratio for subsequent melanoma compared with first melanoma in patients with multiple primary melanomas, clustered on patient and
adjusted for age at diagnosis of lesion, sex, GEM center and all other variables in table. Highest p-value for entry 0.2; 336 cases with complete data
for all variables included in the analysis.
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